Hostname: page-component-7b7567c8c-kwt9d Total loading time: 0 Render date: 2026-11-14T10:56:23.747Z Has data issue: false hasContentIssue false
  • English
  • Français

Practical Guidelines for Vancomycin Usage, With Prospective Drug-Utilization Evaluation

Published online by Cambridge University Press:  02 January 2015

Tayl Drori-Zeides,
David Raveh,
Yechiel Schlesinger and
Amos M. Yinnon
Tayl Drori-Zeides
Affiliation:
Infectious Diseases Unit, Shaare Zedek Medical Center and Hebrew University, Hadassah-Medical School, Jerusalem, Israel
David Raveh
Affiliation:
Infectious Diseases Unit, Shaare Zedek Medical Center and Hebrew University, Hadassah-Medical School, Jerusalem, Israel
Yechiel Schlesinger
Affiliation:
Infectious Diseases Unit, Shaare Zedek Medical Center and Hebrew University, Hadassah-Medical School, Jerusalem, Israel
Amos M. Yinnon*
Affiliation:
Infectious Diseases Unit, Shaare Zedek Medical Center and Hebrew University, Hadassah-Medical School, Jerusalem, Israel
*
Infectious Diseases Unit, Shaare Zedek Medical Center, PO Box 3235, Jerusalem 91031, Israel
Get accessRights & Permissions [Opens in a new window]

Abstract

To strengthen guidelines for vancomycin use, practical guidelines were developed. A prospective survey was conducted of all patients receiving vancomycin during two 1-month periods, 1 year apart, during which significant improvements were noted. Practical guidelines may contribute to appropriateness of vancomycin use, serve as educational tools, and facilitate improved surveillance.

Information

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 21 , Issue 1 , January 2000, pp. 45 - 47
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105–113.CrossRefGoogle Scholar
2.Wenzel, RP, Edmond, MB. Vancomycin-resistant Staphylococcus aureus: infection control considerations. Clin Infect Dis 1998;27:245–251.Google Scholar
3.Hughes, WT, Armstrong, D, Bodey, GP, Brown, AE, Edwards, JE, Feld, R, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997;25:551–573.Google Scholar
4.Yinnon, AM, Schlesinger, Y, Gabbay, D, Rudensky, B. Analysis of 5 years of bacteraemias: importance of stratification of microbial susceptibilities by source of patients. J Infect 1997;35:17–23.Google Scholar
5.Dajani, AS, Taubert, KA, Wilson, W, Bolger, AF, Bayer, A, Ferrieri, P, et al. Prevention of bacterial endocarditis. Recommendations of the American Heart Association. JAMA 1997;277:1794–1801.Google Scholar
6.Threlkeld, MG, Cobbs, CG. Infectious disorders of prosthetic valves and intravascular devices. In: Mandeli, GL, Bennett, JE, Dolin, R, eds. Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill Livingstone; 1995:783–793.Google Scholar
7.Fekety, R. Vancomycin and teicoplanin. In: Mandeli, GL, Bennett, JE, Dolin, R, eds. Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill Livingstone Inc; 1995.Google Scholar
8.Ena, J, Dick, RW, Jones, RN, Wenzel, RP. The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. JAMA 1993;269:598–602.CrossRefGoogle Scholar
9.Peto, RR. Examining vancomycin use in hospitalized medicare patients in the United States. APUA Newsletter 1997;15:1–2.Google Scholar
10.Watanakunakorn, C. Prescribing pattern of vancomycin in a community teaching hospital with low prevalence of vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1997;18:767–769.Google Scholar